James is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. James previously headed Warburg Pincus LLC's medical technology private equity practice where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. Historical investments include: American Medical Systems Holdings, Inc. (AMMD), Coley Pharmaceutical Group, Inc. (COLY sold to Pfizer), The Medicines Company (MDCO), NeXagen, Inc. (NXGN/NXTR sold to GILD), OsteoBiologics, Inc. (sold to Smith & Nephew plc), Oxford GlycoSciences, plc (OGSI sold to CLL), Transkaryotic Therapies, Inc. (TKTX sold to SHPGY), Visible Genetics, Inc. (VGIN sold to BAY), Wright Medical Group, Inc. (WMGI), and Xomed Surgical Products, Inc. (XOMD sold to MDT). He is currently a board member of CAS Medical Systems, Inc., Clarus Therapeutics, Inc., Galil Medical Ltd., and InnoPharma, Inc. Prior to joining Warburg, James was a Vice President at Goldman Sachs International in London. James also serves as a Member of the Board of Directors at the Second Stage Theatre in New York City and The Children's Hospital at Montefiore. He graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received an M.Sc. in Economics from the London School of Economics.